Cimetidine TAGAMET
200*, 400, 600 mg tab; 15 mg/ml soln

- Risk Factor: no evidence of risk (in animal studies or uncontrolled human studies)
- Drug Interactions (DI): inhibition of CYP3A4 system e.g. warfarin, phenytoin, theophylline, etc. (Cimetidine has minor effect on the CYP3A4 system; nizatidine/famotidine little or no effect on CYP3A4 system).
- Space antacid administration 30-60 minutes apart from H2RA’s.

Famotidine PEPCID
10, 20 mg tab; 20mg/40mg Vial

- Risk Factor: no evidence of risk (in animal studies or uncontrolled human studies)
- Drug Interactions (DI): inhibition of CYP3A4 system e.g. warfarin, phenytoin, theophylline, etc. (Famotidine is a more specific inhibitor of CYP2C19 than Cimetidine). Inhibition of CYP2C19 is of clinical significance, as the isomer of omeprazole is a CYP2C19 substrate.

Nizatidine AXID
150, 300 mg cap

- Risk Factor: no evidence of risk (in animal studies or uncontrolled human studies)
- Drug Interactions (DI): inhibition of CYP3A4 system e.g. warfarin, phenytoin, theophylline, etc. (Nizatidine has little or no effect on CYP3A4 system; famotidine has no effect on CYP3A4 system).

Ranitidine ZANTAC
150, 300 mg tab; 15 mg/ml oral solution (50mg Vial)

- Risk Factor: no evidence of risk (in animal studies or uncontrolled human studies)
- Drug Interactions (DI): inhibition of CYP3A4 system e.g. warfarin, phenytoin, theophylline, etc. (Ranitidine has minor effect on the CYP3A4 system).

Proton Pump Inhibitors (PPI’s):
GERD: often od rather than bid dose needed.

**Esomeprazole NEXUM**
20, 40 mg Delayed Release tab

- Risk Factor: no evidence of risk (in animal studies or uncontrolled human studies)
- Drug Interactions (DI): inhibition of CYP2C19 (7% of phenytoin, diazepam, warfarin).

**Lansoprazole PREVACID**
15, 30 mg Delayed Release cap

- Risk Factor: no evidence of risk (in animal studies or uncontrolled human studies)
- Drug Interactions (DI): inhibition of CYP2C19 (7% of phenytoin, diazepam, warfarin).

**Omeprazole LOSEC,APO**
10mg, 20mg Delayed Release tab

- Risk Factor: no evidence of risk (in animal studies or uncontrolled human studies)
- Drug Interactions (DI): inhibition of CYP2C19 (7% of phenytoin, diazepam, warfarin).

**Pantoprazole PANTOLOC**
40mg Enteric tab, 20mg* tab; 40mg Vial

- Risk Factor: no evidence of risk (in animal studies or uncontrolled human studies)
- Drug Interactions (DI): inhibition of CYP2C19 (7% of phenytoin, diazepam, warfarin).

**Rabeprazole PARIET**
10 mg, 20 mg*, 20(40)mg Enteric coated tab

- Risk Factor: no evidence of risk (in animal studies or uncontrolled human studies)
- Drug Interactions (DI): inhibition of CYP2C19 (7% of phenytoin, diazepam, warfarin).

Cost = total cost in Sask.; Considerations of cost should be given to the potential for shorter duration of therapy & of PPIs vs H2RAs. No = not covered by NIHB. Yes = covered by NIHB. See OTC for all no/no exceptions. See www.nibhpriteria.com for all drug interaction advice.
Acid Suppression - Comparison Chart Supplement

The Rx Files - Loren Regier, Brenda Schuster

References

1. AHFS 2004, Micromedix 2004
5. AHFS 2003, Micromedix 2004